ArticleEuropean journal of nuclear medicine and molecular imaging2017
Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.European radiology · 2022Pooled it
- 68Ga-Prostate-specific membrane antigen (psma) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Article
- PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [European journal of nuclear medicine and molecular imaging · 2025Article
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?Bioengineering (Basel, Switzerland) · 2024Review
- Application of next-generation imaging in biochemically recurrent prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- "One Method to Label Them All": A Single Fully Automated Protocol for GMP-CompliantCurrent radiopharmaceuticals · 2024Article
- Article
- Preclinical comparative study of [Scientific reports · 2022Article
- Diagnostic Performance and Clinical Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.Frontiers in oncology · 2022Article
- Differences in Distribution and Detection Rate of the [Pharmaceuticals (Basel, Switzerland) · 2021Article
- Evaluation of Quantitative Ga-68 PSMA PET/CT Repeatability of Recurrent Prostate Cancer Lesions Using Both OSEM and Bayesian Penalized Likelihood Reconstruction Algorithms.Diagnostics (Basel, Switzerland) · 2021Article
- Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions ofDiagnostics (Basel, Switzerland) · 2021Article
- Validation of HPLC method for the determination of chemical andradiochemical purity of aTurkish journal of chemistry · 2021Article
- Detection Rate ofBiomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [
methodsWe performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [
resultsMedian PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.